Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX), a $25.23 million market cap biotechnology company whose stock has gained over 2.5% in the past week, announced on Friday that its DehydraTECH technology demonstrated improved brain biodistribution of fluorescently tagged semaglutide in a rodent study compared to conventional oral formulations. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimates, with analysts setting price targets between $4 and $8 per share.
The study revealed that DehydraTECH-processed semaglutide achieved higher fluorescent signal intensity in the brain across all tested doses compared to equivalent RybelsusⓇ compositions. Notably, the 5mg DehydraTECH formulation showed higher brain semaglutide levels than the 15mg RybelsusⓇ equivalent. InvestingPro data shows the company maintains strong financial flexibility with more cash than debt on its balance sheet and a healthy current ratio of 3.9x, providing runway for continued research and development. Subscribers can access 8 additional ProTips and comprehensive financial metrics on the platform.
Researchers examined key brain regions where semaglutide is known to interact, including the brainstem, hypothalamus, and circumventricular organs. All three DehydraTECH doses displayed fluorescence above control groups, while only the highest RybelsusⓇ equivalent dose (15mg/kg) surpassed controls.
"We are delighted to now see early evidence of this through more detailed fluorescent imaging with DehydraTECH-semaglutide which may help to explain the performance benefits in safety and efficacy we have witnessed in our related human clinical testing to-date," said John Docherty, Lexaria President and CSO.
The findings are significant as GLP-1 drug performance increasingly involves brain neurochemistry. Studies have shown semaglutide regulates body weight through activation of GLP-1 receptors on brain nuclei affecting food intake and energy expenditure.
The preclinical pilot study used Sprague Dawley rats to evaluate biodistribution through non-invasive whole-body imaging and organ analysis. Researchers tracked the fluorescently tagged semaglutide in tissues known to express GLP-1 receptors, including the brain, pancreas, lung, kidney, liver, and heart.
The study was conducted by an independent animal research facility specializing in pharmacokinetic evaluations. Due to the limited size of this pilot study, the company noted that conclusions were made qualitatively based on visual comparisons without statistical analyses.
This announcement was based on a company press release statement. While the company posted impressive revenue growth of nearly 50% in the last twelve months, InvestingPro analysis indicates ongoing profitability challenges. The company’s next earnings report is scheduled for October 29, 2025, where investors will be watching for updates on the commercialization progress of its technology portfolio.
In other recent news, Lexaria Bioscience Corp. announced the completion of patient dosing in its Phase 1b GLP-1 study in Australia. This milestone marks the end of all patient dosing and clinical testing, with the company now entering the laboratory analysis phase. Thousands of samples collected from 126 overweight, obese, pre- or type 2 diabetic patients are being processed, and Lexaria remains blinded to the data until the database work is completed. Meanwhile, H.C. Wainwright adjusted its price target for Lexaria Bioscience, lowering it to $4.00 from $5.00, while maintaining a Buy rating. This adjustment follows interim results from the company’s ongoing study, focusing on specific drug arms. Additionally, Lexaria’s DehydraTECH technology has shown promise in reducing side effects in leading GLP-1 drugs, addressing significant patient retention challenges in the sector. The company also reported positive partial results from a human pilot study comparing its oral DehydraTECH-processed liraglutide to the conventional injected Saxenda. These developments highlight Lexaria’s ongoing research efforts and the potential impact of its technology on the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.